TITLE

H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study

AUTHOR(S)
Farez, Mauricio F; Ysrraelit, Mar�a C; Fiol, Marcela; Correale, Jorge
PUB. DATE
February 2012
SOURCE
Multiple Sclerosis Journal;Feb2012, Vol. 18 Issue 2, p254
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the study on the effects of the H1N1 influenza vaccines in patients with multiple sclerosis (MS). It states that there was no association between H1N1 immunization and increased exacerbation rate in MS which was the conclusion of the study. It discusses H1N1 influenza vaccines side-effects, exacerbation of MS, and immunization.
ACCESSION #
71179625

 

Related Articles

  • H1N1 immunisation: too much too soon? COLLIGNON, PETER // Natural Health & Vegetarian Life;Winter2010, p34 

    In this article, the author comments on the risks and adverse effects of H1N1 vaccination prompted by the swine flu outbreak in Australia in the winter of 2009. It discusses the findings of an Australian H1N1 vaccine trial of adults indicating that more than half of the Australian population are...

  • Determinants of Refusal of A/H1N1 Pandemic Vaccination in a High Risk Population: A Qualitative Approach. d'Alessandro, Eugenie; Hubert, Dominique; Launay, Odile; Bassinet, Laurence; Lortholary, Olivier; Jaffre, Yannick; Sermet-Gaudelus, Isabelle // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: Our study analyses the main determinants of refusal or acceptance of the 2009 A/H1N1 vaccine in patients with cystic fibrosis, a high-risk population for severe flu infection, usually very compliant for seasonal flu vaccine. Methodology/Principal Findings: We conducted a qualitative...

  • Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands. van Puijenbroek, Eugène P.; Broos, Nancy; van Grootheest, Kees // Drug Safety;2010, Vol. 33 Issue 12, p1097 

    Background: In November 2009, a vaccination campaign against Influenza A (H1N1) was started in the Netherlands. The accelerated registration procedure of the vaccines used in this campaign and the use of these vaccines on a large scale indicated a need for real-time safety monitoring. Objective:...

  • Fever Following Immunization with Influenza A (H1N1) Vaccine in Children: A Survey-Based Study in the Netherlands. Broos, Nancy; van Puijenbroek, Eugène P.; van Grootheest, Kees // Drug Safety;2010, Vol. 33 Issue 12, p1109 

    Background: In November 2009, all children in the Netherlands from 6 months up to 4 years of age were indicated to receive the Influenza A (H1N1) vaccine. Fever is a common adverse event following immunization in children. Pandemrix®, an inactivated, split-virus influenza A (Hi N 1) vaccine,...

  • The Safety of H1N1 Vaccine in Children in Saudi Arabia: A Cohort Study Using Modem Technology in a Developing Country. Aljadhey, Hisham; Alyabsi, Mesnad; Alrwisan, Adel; Alqahtani, Nasser; Almutairi, Reem; Al Tawil, Esraa; Adam, Mansour; Shakir, Saad; Aljeraisy, Majed; Al-Blowi, Ali; Alkhashan, Hesham; Albogami, Yasser; Murray, Michael D. // Drug Safety;2012, Vol. 35 Issue 7, p555 

    Background: With its rapid introduction in 2009, concerns about the safety of the H1N1 vaccines have been raised. Data were especially limited on the pediatric safety of H1N1 vaccine in Saudi Arabia. Objectives: The objectives of this study were to investigate the safety of the H1N1 vaccine...

  • Exciting advances in immunisation. Taylor, Lynn // New Zealand Doctor;2/9/2011, p25 

    The article discusses the highlights of the Ninth Canadian Immunisation Conference hosted by the Public Health Agency of Canada in Quebec in December 2011. The four-day programmed discussed several topics that included H1N1 influenza, human papillomavirus (HPV), and invasive pneumococcal disease...

  • Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials. Mallory, Raburn M.; Malkin, Elissa; Ambrose, Christopher S.; Bellamy, Terramika; Shi, Li; Yi, Tingting; Jones, Taff; Kemble, George; Dubovsky, Filip // PLoS Clinical Trials;Oct2010, Vol. 7 Issue 10, Special section p1 

    Background: The safety, tolerability, and immunogenicity of a monovalent intranasal 2009 A/H1N1 live attenuated influenza vaccine (LAIV) were evaluated in children and adults. Methods/Principal Findings: Two randomized, double-blind, placebo-controlled studies were completed in children (2-17 y)...

  • Pandemrix linked to narcolepsy in children, adolescents.  // Reactions Weekly;2/12/2011, Issue 1338, p4 

    The article focuses on a study released by the Finnish National Institute of Health and Welfare which found an increase risk of developing narcolepsy among children and adolescents who were vaccinated with the Pandemrix influenza A virus vaccine-H1N1. The National Narcolepsy Task Force stated...

  • Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 Influenza pandemic. Magalhaes, Isabelle; Eriksson, Mikael; Linde, Charlotte; Muhammad, Rashid; Rane, Lalit; Ambati, Aditya; Axelsson-Robertson, Rebecca; Khalaj, Bahareh; Alvarez-Corrales, Nancy; Lapini, Giulia; Montomoli, Emanuele; Linde, Annika; Pedersen, Nancy L.; Maeurer, Markus // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background Previous exposures to flu and subsequent immune responses may impact on 2009/2010 pandemic flu vaccine responses and clinical symptoms upon infection with the 2009 H1N1 pandemic H1N1 influenza strain. Qualitative and quantitative differences in humoral and cellular immune responses...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics